

**Curriculum Vitae  
David L. Bartlett, M.D.  
University of Pittsburgh  
School of Medicine**

**BIOGRAPHICAL**

<b>Name:</b>	David L. Bartlett	<b>Birth date:</b>	November 5, 1961
<b>Home Address:</b>	504 Old Orchard Trail Pittsburgh, PA 15238	<b>Birth place:</b>	Ann Arbor, MI
<b>Home Phone:</b>	412-767-5571	<b>Citizenship:</b>	USA
<b>Business Address:</b>	University of Pittsburgh Dept. of Surgery 5150 Centre Avenue UPMC Cancer Pavilion, Rm. 459 Pittsburgh, PA 15232	<b>E-Mail:</b>	bartlettddl@msx.upmc.edu
		<b>Business Phone:</b>	412-692-2852
		<b>Business Fax:</b>	412-692-2520

---

**EDUCATION and TRAINING**

**Undergraduate:**

1979-1983	Rice University Houston, Texas	B.A., 1983 Cum Laude Roy Scholar	Roy Scholar
-----------	-----------------------------------	--	-------------

**Graduate:**

1983-1987	University of Texas Medical School at Houston Houston, Texas	M.D., 1987 Alpha Omega Alpha Sandoz Award for Academic Achievement	Medicine
-----------	--	---	----------

**Post-Graduate:**

1987 - 1993	Hospital of the University of Pennsylvania Philadelphia, Pennsylvania	Clyde Barker, MD	Surgery Resident
1993 - 1995	Memorial Sloan-Kettering Cancer Center New York, NY	Murray Brennan, MD Fellow	Surgical Oncology

**Research Fellowships:**

1984-1987	M.D. Anderson Hospital Houston, TX	J. M. Keating, MD Fellow	Department of Developmental Therapeutics
1989-1991	Hospital of the University of Pennsylvania Philadelphia, PA	Michael Torosian, MD Fellow	Harrison Dept. of Surgical Research
1989-1991	National Institutes of Health Department of Surgery Hospital of the University Of Pennsylvania	Michael Torosian, MD Research Fellowship IT32CA09619	Surgical Oncology

**Clinical Fellowship:**

1993 - 1995	Memorial Sloan-Kettering Cancer Center New York, NY	Murray Brennan, MD Fellow	Surgical Oncology
1994 – 1995	American Cancer Society	Murray Brennan, MD Fellow Award # 94-138-1	Clinical Oncology

**APPOINTMENTS and POSITIONS**

7/1/95 - 6/30/96	National Cancer Institute Surgery Branch	Special Expert
7/1/96 – 10/01	National Cancer Institute Surgery Branch	Senior Investigator
7/1/96- 10/01	Uniformed Services University of Health Sciences	Assistant Professor
10/01 – present	University of Pittsburgh Department of Surgery	Visiting Associate Professor and Chief, Division of Surgical Oncology
2005 – Present	University of Pittsburgh Department of Surgery	Professor of Surgery Chief, Division of Surgical Oncology

## **CERTIFICATION and LICENSURE**

### **Specialty Certification:**

American Board of Surgeons                      November 1994

### **Medical Licensure:**

Maryland    D47564  
Pennsylvania                                        MD-044852-E

---

## **MEMBERSHIPS in PROFESSIONAL and SCIENTIFIC SOCIETIES**

American Medical Association	1987 - present
Pennsylvania Medical Society	1989 - 1993
Candidate Group - American College of Surgeons	2005- present
Society of Surgical Oncology	1993 - present
Society of Laparoendoscopic Surgeons	1993 - present
Society of University Surgeons	2/2000 - present
American Association for Cancer Research	2004-present

---

## **HONORS**

William Inouye award for excellence in teaching by a surgical resident	1991
Selected as Scientific Program Director, Society of Surgical Oncology Annual Meeting	2005
Elected as Councillor-at-Large on the SSO Executive Council – 3 year term	2006
Appointed Bernard Fisher Chair	2006

---

## **PUBLICATIONS**

### **Refereed Articles:**

1. **Bartlett DL**, Charland SL, Torosian MH: Glucose metabolism and hormone treatment in cancer cachexia. Surgical Forum 42:14-16, 1991.

2. Redmond HP, Schuchter L, **Bartlett DL**, Kelly CJ, Shou J, Leon P, and Daly JM. Anti-neoplastic effects of interleukin-4. *J Surg Res.* 52(4):406-411, 1992.
3. Torosian MH, **Bartlett DL**, Chatzidakis C, Stein TP: Effect of tumor burden on futile glucose and lipid cycling in tumor-bearing animals. *J Surg Res.* 55(1):68-73, 1993.
4. Torosian MH, **Bartlett DL**: Inhibition of tumor metastasis by a circulating suppressor factor. *J Surg Res.* 55(1): 74-79, 1993.
5. Charland SL, **Bartlett DL**, Davis R, Torosian MH: Effect of protein-calorie malnutrition on methotrexate pharmacokinetics. *JPEN* 18(1):45-49, 1994.
6. **Bartlett DL**, Charland S, Torosian MH: Growth hormone, insulin, and somatostatin therapy of cancer cachexia. *Cancer.* 73(5):1499-504, 1994.
7. **Bartlett DL**, Charland S, Torosian MH: Effect of glutamine on tumor and host growth. *Annals of Surgical Oncology.* 2(1):71-76, 1995.
8. **Bartlett DL**, Charland S, Stein TP, Torosian MH: Effect of growth hormone and protein intake on tumor growth and host cachexia. *Surgery.* 117(3):260-267, 1995
9. **Bartlett DL**, Torosian MH: Biochemical and biological effects of somatostatin therapy on tumor growth and host metabolism. *International Journal of Oncology.* 1995.
10. **Bartlett DL**, Conlon K, Gerdes H, Karpeh M: Laparoscopic ultrasound: the best pretreatment staging modality in gastric adenocarcinoma? *Surgery.* 118(3):562-566, 1995.
11. **Bartlett DL**, Cohen A, Huttner R, Torosian MH: Adrenal pseudocyst in pregnancy *Surgery.* 118(3):567-570, 1995.
12. **Bartlett DL**, Charland S, Torosian MH: Reversal of Tumor-Associated Hyperglucagonemia as Treatment for Cancer Cachexia. *Surgery.* 118(1): 87-97, 1995.
13. Charland S, **Bartlett DL**, Torosian MH: A significant methotrexate-glutamine pharmacokinetic interaction. *Nutrition.* 11(2): 175-177, 1995.
14. **Bartlett DL**, Karpeh MJ, Philippa D, Brennan MF: Long term follow-up after curative surgery for early gastric lymphoma *Ann Surg.* 223(1):53-62, 1996.
15. **Bartlett DL**, Fong Y, Fortner JG, Brennan MF, Blumgart LH: Long-term results after resection for gallbladder cancer -- implications for staging and management. *Ann Surg.* 224(5): 639-646, 1996.
16. **Bartlett DL**, Schwartz LH, Klimstra D, Blumgart LH: Diagnosis and treatment of focal nodular hyperplasia. *J Hep Bil Pancr Surg.* 3:111-121, 1996.

17. **Bartlett DL**, Fong Y, Blumgart LH: Complete resection of the caudate lobe of the liver: technique and results. Br J Surg 83: 1076-1081, 1996.

18. Ma G, Turner E, Jaskowiak N, Sarraf P, **Bartlett DL**, Fraker D, Alexander HR: Obese gene expression is acutely regulated by tumor necrosis factor during sublethal endotoxemia in mice. *Surg Forum*. 47:17-20, 1996.
19. Alexander HR, Fraker DL, **Bartlett DL**: Isolated Limb Perfusion for Malignant Melanoma. *Seminars in Surgical Oncology*. 12: 416-428, 1996.
20. Ma GY, **Bartlett DL**, Reed E, Figg WD, Lush RM, Lee KB, Libutti, SK, Alexander HR: Continuous Hyperthermic Peritoneal Perfusion with Cisplatin for the Treatment of Peritoneal Mesothelioma. *Cancer J Sci Am*. 3: 174-179, 1997.
21. Vargas HI, Kavhoussi LR, **Bartlett DL**, Wagner JR, Venzon DJ, Fraker DL, Alexander HR, Linehan MW, Walther MM: Laparoscopic Adrenalectomy: A New Standard of Care *J Urology*. 79: 673-678, 1997.
22. **Bartlett DL**, Ma GY, Alexander HR, Libutti SK, Fraker DL,: Isolated Limb Reperfusion with Tumor Necrosis Factor and Melphalan for Extremity Melanoma after Failure of Isolated Limb Perfusion with Chemotherapeutics *Cancer*. 80: 2084-2990, 1997.
23. Brown CK, **Bartlett DL**, Doppman JL, Gorden P, Libutti SK, Fraker DL, Shawker TH, Skarulis MC, Alexander HR: Intra-arterial Calcium Stimulation and Intraoperative Ultrasonography in the Localization and Resection of Insulinomas. *Surgery*. 122: 189-1194, 1997.
24. Wu PC, Alexander HR, **Bartlett DL**, Doppman JL, Fraker DL, Norton JA, Gibril F, Fogt F, Jensen RT: A Prospective Analysis of the Frequency, Location, and Curability of Ectopic (non-pancreaticoduodenal, non-nodal) Gastrinoma Surgery. 122: 1176-1182, 1997.
25. Libutti SK, **Bartlett DL**, Doppman JL, Fraker DL, Marx S, Spiegel A, Skarulis M, Alexander HR: The Role for Thyroid Resection During Reoperation for Persistent or Recurrent Hyperparathyroidism. *Surgery*. 122: 1183-1188, 1997.
26. Alexander HR, **Bartlett DL**, Libutti SK, Fraker, D.L., Moser, T., Rosenberg SA: Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. *J. Clin. Oncol*. 16: 1479-1489. 1998.
27. **Bartlett DL**, Buell JF, Fraker DL, Reed E, Lee KB, Figg WD, Venzon DJ, Alexander HR: Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) with TNF and Cisplatin *Cancer*, 83: 1251-1261, 1998.
28. Alexander, H.R., Fraker, D.L., Norton, J.A., **Bartlett, D.L.**, Tio, L., Benjamin, S.B., Doppman J.L., Goebel, S.U., Serrano, J., Gibril, F., Jensen, R.T. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. *Ann. Surg*. 228, 228-238, 1998.

29. Alexander, H.R., Brown, C.K., **Bartlett, D.L.**, Libutti, S.K., Figg, W.D., Raje, S., Turner, E. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. *Clin.Cancer Res.* 4: 2357-2362, 1998.
30. Doppman, J.L., Skarulis, M.C., Chang, R., Alexander, H.R., **Bartlett, D.L.**, Libutti, S.K., Marx, S.J., Spiegel, A.M. Hypocalcemic stimulation and nonselective venous sampling for localizing parathyroid adenomas: Work in Progress. *Radiology.* 208, 145-151, 1998.
31. Park, B.J., Huang, J., Royalty, D., Libutti, S.K., Skarulis, M.C., Jensen, Fraker, D.L., Gorden, P., Norton, J.A., Alexander, H.R., **Bartlett, D.L.** Operative management of islet cell tumors (ICTS) arising in the head of the pancreas. *Surgery.* 124: 1056-1062, 1998.
32. Libutti, S.K., Choyke, P.L., **Bartlett, D.L.**, Vargas, H.A., Walther, M., Lubensky, I., Glenn, G., Steinberg, S., Linehan, W.M. Alexander, M.D. Pancreatic neuroendocrine tumors associated with von Hippel Lindau: Diagnostic and management recommendations. *Surgery.* 124: 1153-1159, 1998.
33. Alexander, H.R., **Bartlett, D.L.**, Venzon, D.T., Libutti, S.K., Doppman, J.L., Fraker, D.L., Norton, J.A., Gibril, F., Jensen, R.T. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation and resection for Zollinger-Ellison syndrome (ZES). *Surgery.* 124: 1160-116, 1998.
34. Cho, H-K., Lush, R.M., **Bartlett, D.L.**, Alexander, H.R., Wu, P.C., Libutti, S.K., Lee, K.B., Venzon, D.J., Bauer, K.S., Reed, E., Figg, W.D. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. *J. Clin. Pharm.* 39: 1-8, 1999.
35. Steller, M.A., Egorin, M.J., Trimble, E.L., **Bartlett, D.L.**, Zuhowski, E.G., Alexander, H.R., Dedrick, R.L. A pilot phase I trial of continuous hyperthermic peritoneal perfusion (CHPP) with high-dose carboplatin (CBDCA) as primary treatment of patients with small volume residual ovarian cancer. *Cancer Chemother Pharmacol.* 43: 106-114, 1999.
36. Berger, A.D., Libutti, S.K., **Bartlett, D.L.**, Skarulis, M.G., Marx, S.J., Spiegel, A.M., Doppman, J.L., Alexander, H.R. Heterogenous gland size in sporadic multiple gland parathyroid hyperplasia. *J. Am. Coll Surg.*, 188: 382-389, 1998.
37. Puhlmann, M., Gnant, M., Brown, C.K., Alexander, H.R., **Bartlett, D.L.** Thymidine kinase deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor directed gene therapy. *Hum Gene Ther.* 10: 649-657, 1998.
38. Park, B.J., Alexander, H.R., Libutti, S.K., Wu, P., Royalty, D., Kranda, K., **Bartlett, D.L.** Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). *Ann Surg Oncol*, 16: 582-590, 1999.

39. Masucci, I.P., Calis, K.A., **Bartlett, D.L.**, Alexander, H.R., Merryman, P.K., Cullinane, A.M., Horne, M.K. Thrombocytopenia after isolated limb or hepatic perfusions with melphalan: the risk of heparin-induced thrombocytopenia. *Ann Surg Oncol*, 6: 476-480, 1999
40. Park, B.J., Brown, C.K., Alexander, H.R., Horti, J., Raje, S., Figg, W.D., **Bartlett, D.L.** Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. *Hum Gene Ther*, 10: 889-898, 1999.
41. Wu, P.C., McCart, J.A., Turner, E., Libutti, S.K., **Bartlett, D.L.**, Alexander, H.R. Isolated organ perfusion does not result in systemic-microembolization of tumor cells.. *Ann. Surg. Oncol.* 6: 658-663, 1999.
42. Gnant, MFX., Puhlmann, M., Alexander Jr, H.R., **Bartlett, DL.** Systemic Administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. *Cancer Res.* 59: 3396-3404, 1999.
43. Riker, A, **Bartlett, DL.** Pancreaticoduodenectomy for chronic pancreatic in a patient with obstruction of the bile duct, duodenum and portal vein: A case report and review of literature. *Hepatogastroenterology*, 46: 2005-2010, 1999.
44. Gnant, MFX, Berger, AC., Huang, J., Puhlmann, M., Wu, PC., Merino, MJ., **Bartlett, DL.**, Alexander, HR., Libutti, SK. Sensitization of tumor necrosis factor alpha (TNF) resistant human melanoma by tumor specific in vivo transfer of the gene encoding for endothelial monocyte activating polypeptide II (EMAP-II) using recombinant vaccinia virus. *Cancer Res.* 59: 4668-4674, 1999
45. Gnant, MFX, Puhlmann, M., Wu, PC., Merino, MJ., **Bartlett, DL.**, Alexander Jr., HR Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases. *Ann. Surg.* 230: 352-361, 1999
46. Feldman, AL, Alexander Jr., HR., **Bartlett, DL.**, Fraker, DL, Libutti, SK. Management of extremity recurrence after complete response to isolated limb perfusion (ILP) in patients with melanoma. *Ann Surg Oncol.* 6: 562-567, 1999
47. Gnant, MFX, Noll, LA., Terrill, Wu, PC., Berger, AC., Nguyen, H.Q., Lans, TE., Flynn, BM., Libutti, SK., **Bartlett, DL.**, Alexander Jr., HR. Isolated hepatic perfusion for lapine liver metastases - impact of hyperthermia on permeability of tumor neovasculature. *Surgery* 126: 890-900, 1999.
48. Feldman, A.L., Sharaf, R.N., Skarulis, M.C., **Bartlett, D.L.**, Libutti, S.K., Weinstein, L.S., Marx, S.J., Norton, J.A., Fraker, D.L., Alexander, H.R. Results of heterotopic parathyroid



autotransplantation: A 13-year experience. *Surgery*, 126: 1042-1048, 1999

49. Zeh, H., Choyke, P.S., Alexander, H.R., **Bartlett, D.L.**, Libutti, S.K., Chang, R. Summers, R.M. Gadolinium-enhanced 3D MRA prior to isolated hepatic perfusion for metastases. *J Comput Assist Tomogr* 23(5): 664-669, 1999.
50. Libutti, S.K., Alexander, H.R., **Bartlett, D.L.**, Sampson, M.L., Ruddel, M.E., Skarulis, M., Marx, S.J., Spiegel, A.M., Simmonds, W., Remaley, A.T. Kinetic analysis of the rapid intraoperative parathyroid hormone assay in patients during operation for hyperparathyroidism. *Surgery*, 126(6): 1145-1150, 1999.
51. Gnant, M.F., Noll, L.A., Irvine, K.R., Puhlmann, M., Terrill, R.E., Alexander, H.R., Jr., **Bartlett, D.L.** Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. *J Natl Cancer Inst.* 91(20): 174-1750, 1999.
52. Libutti SK, **Bartlett DL**, Fraker DL, Alexander HR: Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. *J Am Col Surg*, 2000.
53. Alexander, H.R., Libutti, S.K., **Bartlett, D.L.**, Puhlmann, M., Fraker, D.L., Bachenheimer, L.C. A Phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. *Clin Cancer Res.* In Press, 2000
54. Puhlmann, Brown C, Gnant, M., Huang, J., Libutti, S.K., Alexander HR, **Bartlett DL**: Vaccinia as a vector for tumor directed gene therapy: Biodistribution of a thymidine kinase deleted mutant. *Cancer Gene Ther.*, 7: 66-73, 2000
55. **Bartlett, D.L.** Treatment of patients with hepatic metastases. *Cancer J of Sci Am.* 6: S169-S176, 2000. Feldman, A.L., Restifo, N.P., Alexander, H.R., **Bartlett, D.L.**, Hwu, P., Seth, P., Libutti, S.K. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. *Cancer Res.* 60: 1503-1506, 2000.
56. Feingold, D.L., Alexander, H.R., Chen, C.C., Libutti, S.K., Shawker, T.H., Simonds, W.F., Marx, S.J., Skarulis, M.C., Doppman, J.L., Schrupp, D.S., **Bartlett, D.L.** Ultrasound and sestamibi scan as the only pre-operative imaging tests in re-operation for parathyroid adenomas. *Surgery*. 2000 Dec;128(6):1103-9;discussion 1109-10.
57. McCart, J.A., Puhlmann, M., Lee, J., Hu, Y., Libutti, S.K., Alexander, H.R., **Bartlett, D.L.** Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. *Gene Ther*, In Press, 2000.
58. **Bartlett, D.L.**, Libutti, S.K., Figg, W.D., Fraker, D.L., Alexander, H.R. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. *Surgery*, 2000.

59. McCart, J.A., Ward, J.M., Lee, J., Hu, Y., Alexander, H.R., Libutti, S.K., Moss, B., **Bartlett, D.L.**, Systemic cancer therapy with a tumor selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. *Cancer Res.* 2001 Dec 15; 61(24):8751-7
60. Feldman, AL, Alexander, HR, **Bartlett, DL**, Kranda, KC, Miller, MS, Costouros, NG, Choyke, PL, and Libutti, SK. A Prospective Analysis of Plasma Endostatin Levels in Colorectal Cancer Patients with Liver Metastases. *Annals of Surgical Oncology*, 8(9): 741-745, 2001.
61. Hu Y, Lee J, McCart JA, Xu H, Moss B, Alexander HR, **Bartlett DL**. Yaba-like disease virus: an alternative replication poxvirus vector for cancer gene therapy. *J Virol.* 2001 Nov;75(21):10300-8
62. Kivlen MH, **Bartlett DL**, Libutti SK, Skarulis MC, Marx SJ, Simonds WF, Weinstein LS, Jensen RT, McCart JA, Naik AM, Kranda KC, Brennan MF, Norton JA, Fraker DL, Alexander HR. Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1. *Surgery.* 2001 Dec;130(6):991-8
63. Chang E, Alexander HR, Libutti SK, Hurst R, Zhai S, Figg WD, **Bartlett DL**. Laparoscopic continuous hypothermic peritoneal perfusion. *J Am Coll Surg.* 2001 Aug;193(2):225-9.
64. Berger AC, Gibril F, Venzon DJ, Doppman JL, Norton JA, **Bartlett DL**, Libutti SK, Jensen RT, Alexander HR. Prognostic value of initial fasting serum gastrin levels in patients with Zollinger-Ellison syndrome. *J Clin Oncol.* 2001 Jun 15;19(12):3051-7.
65. Lans TE, **Bartlett DL**, Libutti SK, Gnant MF, Liewehr DJ, Venzon DJ, Turner EM, Alexander HR. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. *Clin Cancer Res.* 2001 Apr;7(4):784-90.
66. **Bartlett DL**, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. *Surgery.* 2001 Feb;129(2):176-87.
67. Libutti SK, Alexander HR Jr, Choyke P, **Bartlett DL**, Bacharach SL, Whatley M, Jousse F, Eckelman WC, Kranda K, Neumann RD, Carrasquillo JA. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. *Ann Surg Oncol.* 2001 Dec;8(10):779-86.
68. Zeh, H J, **Bartlett, DL**. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. *Cancer Gene Therapy* (2002) 9, 1001-1012.

69. Elaraj DM, Remaley AT, Simonds WF, Skarulis MC, Libutti SK, **Bartlett DL**, Venzon DJ, Marx SJ, Alexander H. Utility of rapid intraoperative parathyroid hormone assay to predict severe postoperative hypocalcemia after reoperation for hyperparathyroidism. *Surgery*. 2002 Dec;132(6):1028-33; discussion 1033-4.
70. Marcos HB, Libutti SK, Alexander HR, Lubensky IA, **Bartlett DL**, Walther MM, Linehan WM, Glenn GM, Choyke PL. Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. *Radiology*. 2002 Dec, 225(3):751-8.
71. McCart JA, Wang ZH, Xu H, Hu Y, Park B, Alexander HR, **Bartlett DL**. Development of a melanoma-specific adenovirus. *Mol Ther*. 2002 Oct;6(4):471-80.
72. Albright SV, McCart JA, Libutti SK, **Bartlett DL**, Alexander HR, Sampson ML, Ruddel ME, Remaley AT. Rapid measurement of insulin using the Abbott IMx: application to the management of insulinoma. *Ann Clin Biochem*. 2002 Sep;39(Pt 5):513-5.
73. Alexander HR Jr, Libutti SK, **Bartlett DL**, Pingpank JF, Kranda K, Helsabeck C, Beresnev T. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. *Cancer*. 2002 Aug 15;95(4):730-6.
74. Friedl J, Puhlmann M, **Bartlett DL**, Libutti SK, Turner EN, Gnant MF, Alexander HR. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. *Blood*. 2002 Aug 15;100(4):1334-9.
75. Hirshberg B, Libutti SK, Alexander HR, **Bartlett DL**, Cochran C, Livi A, Chang R, Shawker T, Skarulis MC, Gorden P. Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. *J Am Coll Surg*. 2002 Jun;194(6):761-4.
76. Lublin M, **Bartlett DL**, Danforth DN, Kauffman H, Gallin JJ, Malech HL, Shawker T, Choyke P, Kleiner DE, Schwartzentruber DJ, Chang R, DeCarlo ES, Holland SM. Hepatic abscess in patients with chronic granulomatous disease. *Ann Surg*. 2002 Mar;235(3):383-91.
77. Elaraj DM, Remaley AT, Simonds WF, Skarulis MC, Libutti SK, **Bartlett DL**, Venzon DJ, Marx SJ, Alexander HR. Utility of rapid intraoperative parathyroid hormone assay to predict severe postoperative hypocalcemia after reoperation for hyperparathyroidism. *Surgery*. 2002 Dec;132(6):1028-33; discussion 1033-4.
78. Alexander HR Jr, Libutti SK, Pingpank JF, Steinberg SM, **Bartlett DL**, Helsabeck C, Beresneva T. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. *Clin Cancer Res*. 2003 Dec 15;9(17):6343-9.

79. Feldman AL, Libutti SK, Pingpank JF, **Bartlett DL**, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. *J Clin Oncol*. 2003 Dec 15;21(24):4560-7.
80. Elaraj DM, Skarulis MC, Libutti SK, Norton JA, **Bartlett DL**, Pingpank JF, Gibril F, Weinstein LS, Jensen RT, Marx SJ, Alexander HR. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. *Surgery*. 2003 Dec;134(6):858-64; discussion 864-5.
81. Feldman ED, Wu PC, Beresneva T, Helsabeck C, Rodriguez M, **Bartlett DL**, Libutti SK, Pingpank JF, Alexander HR. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. *J Gastrointest Surg*. 2004 Feb;8(2):200-7.
82. McCart AJ, Mehta N, Scollard D, Reilly RM, Carrasquillo JA, Tang N, Deng H, Miller M, Xu H, Libutti S, Alexander HR, and **Bartlett DL**. Oncolytic Vaccinia Virus Expressing the Human Somatostatin Receptor SSTR2: Molecular Imaging after Systemic Delivery Using <sup>111</sup>In-Pentetreotide. *Molecular Therapy*. 2004 Sept; 10(3): 553.561.
83. Chang E, Chalikonda S, Friedl J, Xu H, Phan GQ, Marincola FM, Alexander HR, and **Bartlett DL**. Targeting Vaccinia to Solid Tumors with Local Hyperthermia. *Human Gene Therapy*. 2005 March 16(3).
84. Koniaris LG, Staveley-O'Carroll KF, Zeh, HJ, Perez E, Jin XL, Maley WR, Zabari G, Bartlett DL, Khanna A, Franceschi D, Schoeniger LO. Pancreaticoduodenectomy in the Presence of Superior Mesenteric Venous Obstruction. *J Gastrointest Surg*. 2005 September - October;9(7):915-921. PMID: 16137584
85. Guo, ZS, A. Naik, M. E. O'Malley, P. Popovic, R. Demarco, Y. Hu, X. Yin, S. Yang, H. J. Zeh, B. Moss, M. T. Lotze, and D. L. **Bartlett**. The Enhanced Tumor Selectivity of an Oncolytic Vaccinia Lacking the Host Range and Anti-Apoptosis Genes SPI-1 and SPI-2. *Cancer Res*. 2005 Nov 1;65(21): 9991-8.
86. Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, **Bartlett DL**, Kirkwood JM, Lotze, MT, Herberman RB. Natural-killer dendritic cell cross-talk in cancer immunotherapy. *Expert Opin Biol Ther*. 2005;5(10): 1305-15

#### **Invited Chapters/Articles:**

1. **Bartlett DL**, Charland SL, Torosian MH: Glucose metabolism and hormone treatment in cancer cachexia. *Surgical Forum* 42:14-16, 1991.

2. **Bartlett DL:** Biology of Cancer. In: Essentials of Basic Science in Surgery. Edited by S Fishman and E Savage. Lippincott, Philadelphia, Pa., 1992.
3. Charland SL, **Bartlett DL**, Davis R, Torosian MH: Effect of protein-calorie malnutrition on methotrexate pharmacokinetics. *JPEN* 18(1):45-49, 1994
4. **Bartlett DL:** Somatostatin. In: Protein and Amino Acid Metabolism in Cancer Cachexia. Edited by MF Brennan and P Pisters. R.G. Landes Company, Georgetown, Tx., 1996.
5. **Bartlett DL**, Schwartz LH, Klimstra D, Blumgart LH: Diagnosis and treatment of focal nodular hyperplasia *J Hep Bil Pancr Surg.* 3: 111-121, 1996.
6. Ma G, Turner E, Jaskowiak N, Sarraf P, **Bartlett DL**, Fraker D, Alexander HR: Obese gene expression is acutely regulated by tumor necrosis factor during sublethal endotoxemia in mice. *Surg Forum.* 47: 17-20, 1996.
7. **Bartlett DL:** Growth hormone in the Oncology Patient. In: Growth Hormone in Critical Illness. Edited by MH Torosian. R.G. Landes Company, Georgetown, Tx., 1996.
8. **Bartlett DL:** Tumours of the Gallbladder. In: Surgery of the Liver and Biliary Tract. Edited by LH Blumgart and Y Fong. Churchill Livingstone, London. 1996. Section 8; Ch.67.
9. Alexander HR, **Bartlett DL**, Fraker DL, Libutti SK: Regional Treatment Strategies for Unresectable Primary or Metastatic Cancer Confined to the Liver. In: UPDATES: Principles and Practice of Oncology. 10(8) Edited by SA Rosenberg. Lippincott-Raven, Philadelphia August, 1996.
10. Brown C, Park B, Alexander HR, **Bartlett DL:** High Level Tissue-Specific Gene Expression in Melanoma Cells with T7 RNA Polymerase Transcriptional Amplification. *Surgical Forum.* 811-814, 1997.
11. Alexander, H.R., Jr., **Bartlett, D.L.**, Libutti, S.K: Isolated hepatic perfusion: A potentially effective treatment for patients with metastatic or primary cancers confined to the liver. *Canc. J. from Sci. Am.* 4: 2-11, 1998.
12. Riker A, Libutti SK, **Bartlett DL:** Advances in the early detection, diagnosis and staging of pancreatic cancer. *Surg. Oncol.* 6, 157-169, 1998.
13. Zeh, H.J., **Bartlett, D.L.** Sarcoma. In: Current Cancer Therapeutics,. 3<sup>rd</sup> Edition, M.T. Lotze, Ed. Current Medicine, Philadelphia, PA 1998.
14. **Bartlett DL**, Fuller B, Fojo A: Adrenal glands. In: Integrated Cancer Management: Surgery, Medical Oncology, and Radiation Therapy. Edited by M.H. Torosian. Marcel Dekker, Inc., New York, NY. Ch. 12, pp 294-321, 1999.

15. Alexander, H.R., **Bartlett, DL**, Libutti, SK. NCI experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity. Regional Chemotherapy. Edited by: M. Markham. Humana Press, Inc., Totowa, NJ, 2000.
16. Alexander, H.R., **Bartlett, D.L.**, Libutti, S.K. National Cancer Institute experience with regional therapy for unresectable primary and metastatic cancer of the liver of peritoneal cavity. In. Current Clinical Oncology: Regional Chemotherapy: Clinical Research and Practice. Ed. Markman, M. Humana Press Inc., Totoway, NJ. Ch. 8 pp 127-150, 2000.
17. Alexander, HR Jr., **Bartlett, DL**, Libutti, SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. *Oncologist*. 2000;5(5):416-24.
18. **Bartlett, D.L.** Treatment of patients with hepatic metastases. *Cancer J of Sci Am*. 6: S169-S176, 2000.
19. **Bartlett, D.L.** Peritoneal Carcinomatosis. In: Principles and Practice of Oncology, Eds. Devita, Hellman, Rosenberg. Lippincott, Williams & Wilkins, Philadelphia, PA. Pub. Ch 49 pp 2561 – 2573. 2001.
20. **Bartlett DL** and Fong Y. Small solitary hepatic metastases: When and how? In: Surgical Management of hepatobiliary and pancreatic disorders. Ed. Graeme J. Poston and Leslie H. Blumgart. Martin Dunitz Ltd. London, England. 2003 Ch. 6 pp 79-92.
21. **Bartlett DL**, Carr BI, Marsh JW. Cancer of the Liver. In: *Principles and Practice of Oncology*, 7<sup>th</sup> edition. Eds. Devita, Hellman, Rosenberg. Lippencott, Williams & Wilkins, Philadelphia. 2005 Section 4 pp 986-1008.
22. **Bartlett DL**, Carr BI, Marsh JW. Cancer of the Billiary Tree. In: *Principles and Practice of Oncology*, 7<sup>th</sup> edition. Eds. Devita, Hellman, Rosenberg. Lippencott, Williams & Wilkins, Philadelphia. 2005 Section 5 pp 1009-1034.

#### **Published Abstracts:**

1. **Bartlett DL**, Chatzidakis C, Stein TP, Torosian MH: Effect of the tumor-bearing state on a substrate cycle in the rat. *Proceedings, Society of Surgical Oncology* 36:270, 1990.(Presentation, Washington, D.C., 1990)
2. **Bartlett DL**, Torosian MH: Growth hormone selectively supports host versus tumor growth. *Journal of Cancer Research Clinical Oncology* 116:355, 1990.(Presentation, Hamburg, Germany, 1990)
3. **Bartlett DL**, Kalish E, Torosian MH: Effect of glutamine on tumor and host growth. *Proceedings, Association for Academic Surgery* 24:83, 1990. (Presentation, Houston, Texas, 1990)

4. **Bartlett DL**, Charland S, Kalish E, Perkins M, Torosian MH: Somatostatin and insulin treatment for cancer cachexia. *Journal of Parenteral and Enteral Nutrition* 15(Suppl):30S, 1991. (Presentation, San Francisco, CA, 1991)
5. Charland SL, **Bartlett D**, Davis R, Kalish E, Torosian MH: Effect of protein depletion on methotrexate pharmacokinetics. *Journal of Parenteral and Enteral Nutrition* 15(Suppl):21S, 1991. (Presentation, San Francisco, CA, 1991)
6. **Bartlett DL**, Takoudas T, Torosian MH: Effect of long-term somatostatin on tumor growth and host metabolism. *Journal of Parenteral and Enteral Nutrition* 15(Suppl):30S, 1991. (Presentation, San Francisco, CA, 1991)
7. **Bartlett DL**, Charland S, Torosian MH: Specific metabolic therapy of cancer cachexia. *Proceedings, Society of Surgical Oncology* 44:114, 1991. (Presentation, Orlando, FL, 1991)
8. Torosian MH, **Bartlett DL**, Chatzidakis C, Stein TP: Futile glucose cycling and lipolysis in tumor-bearing animals. *Proceedings, Association for Academic Surgery* 25:82, 1991. (Presentation, Colorado Springs, CO, 1991)
9. **Bartlett DL**, Torosian MH: Inhibition of metastasis by a circulating suppressor factor in tumor-bearing animals. *Proceedings, Association for Academic Surgery* 25:125, 1991. (Presentation, Colorado Springs, CO, 1991)
10. **Bartlett DL**, Charland S, Torosian MH: Differential effect of medium- and long-chain triglycerides on tumor growth and metastasis. *Journal of Parenteral and Enteral Nutrition* (Presentation, Orlando, FL, 1992)
11. Charland SL, **Bartlett DL**, Torosian MH: Glutamine supplementation decreases systemic methotrexate clearance. *Journal of Parenteral and Enteral Nutrition* (Presentation, Orlando, FL, 1992)
12. **Bartlett DL**, Karpeh M, Lemer M, Brennan MF: Adjuvant therapy for early gastric lymphoma Society for Surgery of the Alimentary Tract (Presentation, New Orleans, La.; 1994).
13. **Bartlett DL**, Fong Y, Fortner JG, Blumgart LH, Brennan MF: Radical resection for gallbladder cancer. *Society of Surgical Oncology* (Presentation, Boston, MA; May, 1994)
14. Buell JF, **Bartlett DL**, Venzon D, Reed E, Parker R, Figg D, Lush R, Ma G, Lee KB, Fraker DL, Alexander HR: Continuous hyperthermic peritoneal perfusion (CHPP) with tumor necrosis factor (TNF) and cisplatin (CDDP) for the treatment of peritoneal carcinomatosis (Pca) *Society of Surgical Oncology* (Presentation, Atlanta GA, March, 1996)
15. Libutti SK, Alexander HR, **Bartlett DL**, Rosenberg SA, Fraker DL: Patterns of Local

Failure in Extremity Melanoma after a Complete Response to Isolated Limb Perfusion with Melphalan with or without Tumor Necrosis Factor. American Society of Clinical Oncology (Presentation, Philadelphia PA, May 1996).

16. Ma GY, **Bartlett DL**, Reed E, Figg D, Lush R, Lee KB, Fraker DL, Alexander HR: Continuous Hyperthermic Peritoneal Perfusion (CHPP) with Cisplatin (CDDP) for Treatment of Peritoneal Mesothelioma (PM) American Society of Clinical Oncology (Presentation, Philadelphia PA, May 1996)
17. Fraker DL, Alexander HR, **Bartlett DL**, Rosenberg SA: A Prospective Randomized Trial of Therapeutic Isolated Limb Perfusion (ILP) Comparing Melphalan (M) versus Melphalan, Tumor Necrosis Factor (TNF) and Interferon-gamma (IFN): an Initial Report Society of Surgical Oncology (Presentation, Atlanta GA, March 1996)
18. Vargas HI, Alexander HR, Andrich MP, Turner E, Barker CP, **Bartlett DL**, Rosenberg SA, Fraker DL: Assessment of Perfusate Leak During Isolated Limb Perfusion (ILP) with Tumor Necrosis Factor (TNF) Society of Surgical Oncology.(Presentation, Atlanta GA, March 1996).
19. Ma GY, Alexander HR, **Bartlett DL**, Rosenberg SA, Fraker DL: Isolated Limb Reperfusion (ILRe) with Tumor Necrosis Factor (TNF) and Melphalan (M) for Extremity Melanoma after Failure of Isolated Limb Perfusion (ILP) with Chemotherapeutics Society of Surgical Oncology (Presentation, Atlanta GA, March 1996).
20. Jaskowiak NT, Alexander HR, **Bartlett DL**, Turner EM, Tsigos C, Papanicolaou D, Chrousos GP, Fraker DL: Secondary Cytokine Production and Endocrine Effects after High Dose Intravascular TNF. Cambridge Symposium (Presentation, Hilton Head Island SC, March 1996)
21. Alexander HR, **Bartlett DL**, Reed E, Buell JF, Parker R, Venzon D, Figg WD, Lush R, Lee KB, Fraker DL, Eliot H, Ma G: The Use of Tumor Necrosis Factor in Continuous Hyperthermic Peritoneal Perfusion (CHPP) for the Treatment of Peritoneal Carcinomatosis (PC) Cambridge Symposium (Presentation, Hilton Head Island SC, March 1996)
22. Alexander HR, **Bartlett DL**, Rosenberg SA, Fraker DL: Phase I/II Study of Isolated Hepatic Perfusion (IHP) with Tumor Necrosis Factor (TNF) plus Melphalan to treat Patients with Unresectable Malignancies Confined to the Liver American College of Surgeons (Presentation, San Francisco CA, October 1996).
23. Libutti SK, Vargas HI, Wu P, Turner E, **Bartlett DL**, Eliot H, Brown C, Wong GHW, Stern D, Fraker DL, Alexander HR: Endothelial Monocyte Activating Polypeptide II (EMAP II) induces expression of Tumor Necrosis Factor (TNF) Receptor P55 (R1) by Endothelial Cells Society of Surgical Oncology (Presentation, Chicago IL, March 1997)
24. Libutti SK, **Bartlett DL**, Turner E, Fraker DL, Alexander HR: Isolated Hepatic Perfusion



(IHP) with Tumor Necrosis Factor (TNF) and Melphalan: Complete Vascular Isolation confirmed by Intraoperative Monitoring and Measurements of Cytokine Levels. Society of Surgical Oncology(Presentation, Chicago IL, March 1997)

25. Alexander HR, **Bartlett DL**, Fraker DL, Libutti SK, Moser T, Rosenberg SA: Results of a Phase II Study of Isolated Hepatic Perfusion (IHP) with Tumor Necrosis Factor (TNF) and Melphalan for Unresectable Primary or Metastatic Cancer confined to the Liver Society of Surgical Oncology (Presentation, Chicago IL, March 1997)
26. Alexander HR, **Bartlett DL**, Fraker D, Libutti S, Moser T, Rosenberg S: Isolated Hepatic Perfusion (IHP) with Melphalan and Tumor Necrosis Factor (TNF) to treat Unresectable Cancers confined to the Liver Japanese Surgical Society. (Presentation, Japan, April 1997)
27. Brown CK, **Bartlett DL**, Doppman JL, Gorden P, Libutti SK, Fraker DL, Shawker TH, Skarulis MC, Alexander HR: Intra-arterial Calcium Stimulation and Intraoperative Ultrasonography in the Localization and Resection of Insulinomas. American Association of Endocrine Surgeons (Presentation, Baltimore, April 1997)
28. Wu PC, Alexander HR, **Bartlett DL**, Doppman JL, Fraker DL, Norton JA, Gibril F, Fogt F, Jensen RT: A Prospective Analysis of the Frequency, Location, and Curability of Ectopic (non-pancreaticoduodenal, non-nodal) Gastrinoma American Association of Endocrine Surgeons (Presentation, Baltimore, April 1997)
29. Libutti SK, **Bartlett DL**, Doppman JL, Fraker DL, Marx S, Spiegel A, Skarulis M, Alexander HR: The Role for Thyroid Resection During Reoperation for Persistent or Recurrent Hyperparathyroidism Surgery. American Association of Endocrine Surgeons (Presentation, Baltimore, April 1997)
30. Pullman M, Brown CK, Alexander HR, **Bartlett DL**: Selective marker gene expression in intraperitoneal tumors using Vaccinia virus. Proc AACR, 38: 176, 1997. American Association of Cancer Research (Presentation, San Diego, CA, May, 1997).
31. Brown CK, Park BJ, Alexander HR, **Bartlett DL**: High Level Tissue-Specific Gene Expression in Melanoma Cells with T7 RNA Polymerase Transcriptional Amplification American College of Surgeons (Presentation, Chicago, October 1997).

32. Brown, C.K., **Bartlett, D.L.**, Libutti, S.K., Turner, E., Figg, D., Raja, S., Alexander, H.R. Augmented Capillary Leak During Isolated Hepatic Perfusion (IHP) Occurs via TNF Independent Mechanisms. Society of Surgical Oncology (Presentation, San Diego, March, 1998).
33. Park, B.J., Brown, C.K., Libutti, S.K., Alexander, H.R., **Bartlett, D.L.** Augmentation of Tissue-Specific Gene Expression in Melanoma Cells Using a Murine Melanocyte-Specific Enhancer (MSE) Society of Surgical Oncology (Presentation, San Diego, March, 1998)
34. Puhlmann, M., Alexander, H.R., Libutti, S.K., **Bartlett, D.L.** Cytotoxicity of Recombinant Vaccinia Viruses (RECCV) Expressing Cytosine Deaminase (CD) or Purine Nucleoside Phosphorylase (PNP) Against Adenocarcinoma Society of Surgical Oncology (Presentation, San Diego, March, 1998)
35. Puhlmann, M., **Bartlett, D.L.**, Libutti, S.K., Fraker, D.L., Alexander, H.R. Treatment of Metastatic Ocular Melanoma (OM) Confined to Liver Using Isolated Hepatic Perfusion (IHP) with Tumor Necrosis Factor (TNF) and Melphalan. Society of Surgical Oncology (Presentation, San Diego, March, 1998)
36. Park, B.J., Huang, J., Royalty, D., Libutti, S.K., Skarulis, M.C., Jensen, R.T., Fraker, D.L., Gorden, P., Norton, J.A., Alexander, H.R., **Bartlett, D.L.** Operative management of islet cell tumors (ICTS) arising in the head of the pancreas. American Association of Endocrine Surgeons (Presentation, Orlando, FL, April, 1998).
37. Libutti, S.K., Choyke, P.L., Bartlett, D.L., Vargas, H.A., Walther, M., Lubensky, I., Glenn, G., Steinberg, S., Linehan, W.M., Alexander, H.R. Pancreatic neuroendocrine tumors associated with von Hippel Lindau: Diagnostic and management recommendations. American Association of Endocrine Surgeons (Presentation, Orlando, FL, April, 1998).
38. Alexander, H.R., **Bartlett, D.L.**, Venzon, D.T., Libutti, S.K., Doppman, J.L., Fraker, D.L., Norton, J.A., Gibril, F., Jensen, R.T. Factors associated with long-term care in patients undergoing operation and resection for Zollinger-Ellison syndrome (ZES) American Association of Endocrine Surgeons (Presentation, Orlando, FL, April, 1998).
39. **Bartlett, D.L.**, Libutti, S.K., Alexander, H.R. Results of isolated hepatic perfusion (IHP) in patients with regionally advanced unresectable colorectal cancer. Society of Surgical Oncology. Presentation, Orlando, FL, March, 1999)
40. McCart, J.A., Puhlmann, M., Lee, J., Libutti, S.K., Alexander, H.R., **Bartlett, D.L.** Anti-tumor activity of a thymidine kinase (TK)-deleted vaccinia virus. Society of Surgical Oncology (Presentation, Orlando, FL, March, 1999).
41. Feldman, A.L., Alexander, H.R., **Bartlett, D.**, Fraker, D., Libutti, S.K. Management of extremity recurrence after complete response to isolated limb perfusion (ILP) in patients with

melanoma. Society of Surgical Oncology. (Presentation, Orlando, FL, March, 1999).

42. Wang, Z.H., Park, B., Hu, Y., Alexander, R., **Bartlett, D.** Melanoma specific gene expression using adenovirus. American Society of Gene Therapy. (Presentation, Washington, D.C., June 1999)
43. Lee, J., Hu, Y., McCart, J.A., Moss, B., Alexander, H.R., **Bartlett, D.L.** A novel replicating pox vector for cancer gene therapy. Society of Surgical Oncology. (Presentation, New Orleans, March 2000)
44. McCart, J.A., Lee, J., Hu, Y., Alexander, H.R., Libutti, S.K., Moss, B., **Bartlett, D.L.** Anti-tumor effect of a combined thymidine kinase/vaccinia growth factor deleted vaccinia virus. American Association for Cancer Research. (Presentation, San Francisco, April, 2000)
45. Lee, J., McCart, J.A., Alexander, H.R., **Bartlett, D.L.** Enhanced vaccinia-mediated antitumor response after specific inhibition of the cellular immune response. American Society of Gene Therapy. (Presentation, Denver, May, 2000)
46. Fiengold, D.L., Alexander, H.R., Chen, C.C., Libutti, S.K., Shawker, T.H., Simonds, W.F., Marx, S.J., Skarulis, M.C., Doppman, J.L., Schrupp, D.S., **Bartlett, D.L.** Ultrasound and sestamibi scan as the only pre-operative imaging tests in re-operation for parathyroid adenomas. American Association of Endocrine Surgeons. (Presentation, Lille, France, June, 2000).
47. A.M. Naik, H. Xu, H.R. Alexander, **D.L. Bartlett**, NCI, NIH. A mutant vaccinia virus with improved tumor selectivity. SSO Cancer Symposium, Washington, DC. 3/15-18/01
48. E. Chang, J. Friedl, H.R. Alexander, **D.L. Bartlett**, Surgery Branch, NCI, NIH. Hyperthermia (HT) Augments vaccinia virus delivery to tumors. SSO Cancer Symposium, Washington, DC. 3/15-18/01
49. S.K. Libutti, H.R. Alexander, P. Choyke, **D.L. Bartlett**, S.L. Bacharach, R.D. Neumann, F. Jousse, M. Whatley, W.H. Eckelman, K. Kranda, J.A. Carrasquillo, NIH. Prospective study of FDG-PET scan, CEA scan and blind second look laparotomy (SLL) for detecting colon cancer recurrence in patients with rising CEA levels. SSO Cancer Symposium, Washington, DC. 3/15-18/01
50. J. Friedl, S.K. Libutti, **D.L. Bartlett**, H.R. Alexander, Surgery Branch, NCI. Effects of tumor necrosis factor (TNF) and hyperthermia (HT) on permeability across endothelial cell monolayers. SSO Cancer Symposium, Washington, DC. 3/15-18/01
51. T. Zogakis, **D.L. Bartlett**, S.K. Libutti, D.J. Leiwehr, S.M. Steinberg, D.L. Fraker, and H.R. Alexander, Surgery Branch and Biostatistics & Data Mgmt. Section, NCI. Factors affecting survival following complete response to isolated limb perfusion (ILP) in patients with in transit melanoma. SSO Cancer Symposium, Washington, DC. 3/15-18/01

52. D.L. Fraker, H.R. Alexander, M. Ross, **D.L. Bartlett**, D. Tyler, L.S. Libutti, A. Boodie, H. Briele, G. Karakousis. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon-gamma. SSO Cancer Symposium, Denver, CO 3/15-18/02
53. M.A. Kavanagh, J. Johns, H.R. Alexander, H. Xu, J.A. McCart, **D.L. Bartlett**, Surgery Branch, NCI, NIH. Improved anti-tumor response and decreased toxicity with a replicating Vaccinia Virus (VV) Expressing Fas Ligand. SSO Cancer Symposium, Denver, CO 3/15-18/02
54. J.A. McCart, H. Xu, M. Puhlmann, M.H. Kivlen, A. Naik, H.R. Alexander, B. Moss, **D.L. Bartlett**. Use of a tumor-selective vaccinia virus mutant to compare cytosine deaminase suicide gene systems. ASGT, Seattle, WA 5/30/01-6/3/01
55. A.M. Naik, J.A. McCart, H. Xu, M.H. Kivlen, G. Langham, C. Emanuel, B. Moss, H.R. Alexander, **D.L. Bartlett**. Intravenous and isolated limb perfusion delivery of tumor selective vaccinia virus mutant in non-human primates. ASGT, Seattle, WA 5/30/01-6/3/01
56. M.H. Kivlen, J.A. McCart, A. Naik, B.M. Ward, M.H. Kershaw, P. Hwu, B. Moss, H. R. Alexander, **D.L. Bartlett**. In vitro attenuation of vaccinia virus by truncation of the A34R envelope protein. ASGT, Seattle, WA 5/30/01-6/3/01
57. Chang, Eugene, Puhlmann, Markus, Alexander, H. Richard, **Bartlett, David L.** Surgery Branch, NCI, NIH. Systemic delivery of a replicating vaccinia expressing purine nucleoside phosphorylase (PNP) treats subcutaneous tumors. AACR Annual Meeting, New Orleans, LA 3/24-28/01
58. R. Alexander, SK Libutti, JF Pingpank, DL Bartlett, c. Helsabeck, K. Kranda, T. Beresnev. Hyperthermic Isolated Hepatic Perfusion (IHP) using Melphalan for Patients with Ocular Melanoma (OM) Metastatic to liver. SSO Cancer Symposium, LA, CA, 3/5-9/03.
59. T Seenivasan, SD Finkelstein, E Sasatomi, JM Kane, PA Swalsky, DL Bartlett. Mutational Fingerprinting by Microdissection Genotyping of Appendiceal Cancers. SSO Cancer Symposium, LA, CA, 3/5-9/03.

#### **Invited Lectureships:**

1. Cryotherapy for Liver Tumors.  
Postgraduate Course at Society of Surgery of the Alimentary Tract (SSAT)  
(San Francisco, CA. May 1996)
2. Techniques and Results of Isolated Hepatic Perfusion  
Chinese National Hepatobiliary and Enteric Surgery Research Center  
Hunan, P.R. China, April, 1997

3. Regional therapy for unresectable liver cancer (Infusion, perfusion, and other techniques).  
Postgraduate course at American College of Surgeons  
"Frontiers in Clinical Oncology"  
(Baltimore, MD, April 1998).
4. Management of Peritoneal Carcinomatosis  
Surgical Grand Rounds  
Montefiore Medical Center  
(New York, NY Jan. 21, 1998)
5. Updates in Gene Therapy for Cancer  
Surgical Grand Rounds  
Hospital of the University of Pennsylvania  
(Philadelphia, PA, April 4, 1998).
6. Basic Science of Oncology, Genetics of Colorectal Cancer, Adrenal Cancer, Laparoscopy in  
Surgical Oncology.  
Salzburg-Cornell Surgical Oncology Seminar  
Salzburg, Austria, Feb. 15-21, 1998)
7. Regional Application of Tumor Necrosis Factor via Isolated Perfusion: Mechanisms of  
Action and Current Clinical Results.  
Clinical Center Ground Rounds, NIH, Bethesda, Maryland  
September 2, 1998
8. Management of Hepatic Metastasis  
National Oncology forum, Chicago, Ill.  
October, 1999
9. Replicating Pox Viruses for Tumor Directed Gene Delivery.  
National Cancer Institute, Seminars in Clinical and Molecular Oncology.  
Bethesda, MD  
January 18, 2000
10. Immunotherapy of Cancer  
Baxter Health Care Chicago, IL  
April, 2000
11. Treatment of Liver Metastases.  
Isolated Hepatic Perfusion Oncology Conference  
Ellis Fischer Cancer Center Lake of the Ozarks, Missouri  
May, 2000

12. "Parathyroid Imaging"  
American Association of Endocrine Surgeons & British Association of Endocrine Surgeons  
in London, England  
05/19/00-05/26/00
13. "Enhanced vaccinia - mediated anti-tumor response after specific inhibition of the cellular  
immune response"  
American Society of Gene Therapy, Denver, CO  
05/31/00-06/02/00
14. "Development of tailor-made cancer therapy"  
US-Japan Workshop; Maui, HI  
02/17/01-02/19/01
15. "Intraperitoneal chemotherapy".  
Gastric Cancer Congress (co-chair), New York, NY  
04/29/01-05/02/01
16. "Systematic delivery of a replicating vaccinia expressing purine nucleoside phosphorylase  
(PNP) treats subcutaneous tumors."  
American Association for Cancer Research in New Orleans, LA  
03/26/01-03/28/2001
17. "Intraperitoneal chemotherapy".  
Gastric Cancer Congress (co-Chair) in New York, NY  
04/29/01-05/02/01
18. "Use of a Tumor-Selective Vaccinia Virus Mutant to Compare Cytosine Deaminase Suicide  
Gene Systems"  
American Society of Gene Therapy, Seattle, Washington  
05/31/01-06/02/01
19. "Vaccinia virus gene therapy".  
Rotterdam Cancer Institute, Rotterdam, the Netherlands  
09/03/01-09/07/01
20. "Management of Hepatic Metastases."  
Georgetown University Hospital Grand Rounds, Washington, D.C.  
November 2001
21. "Regional Perfusion for Cancer."  
Central Surgical Association Annual Meeting, Pittsburgh, PA  
03/07/02

22. "Hyperthermic Perfusion for Regionally Confined Metastatic Cancer."  
UPMC Center for Continuing Education: St. Francis Health System, Pittsburgh, PA  
04/09/02
23. "Adjuvant Therapy for Locally Advanced Pancreatic Cancer".  
UPMC Center for Continuing Education: Dubois Cancer Conference; Dubois, PA  
04/13/02
24. "Adjuvant Therapy for Locally Advanced Pancreatic Cancer".  
UPMC Center for Continuing Education: Brownsville General Hospital; Brownsville, PA  
04/18/02
25. "Hyperthermic Perfusion for Regionally Confined Metastatic Cancer."  
The College of Physicians and Surgeons of Ontario; Toronto, Canada  
04/26/02
26. Tumor Board  
Lee Hospital, Johnstown, PA  
October 3, 2002
27. Tumor Board  
Westmoreland County Hospital  
10/15/02
28. Grand Rounds  
West Penn Allegheny Health System, Pittsburgh, PA  
10/30/02
29. Tumor Board  
Lee Hospital, Johnstown, PA  
10/05/02
30. Presentation to UPMC Cancer Centers Management Assembly  
Hillman Cancer Center, Pittsburgh, PA  
12/12/02
31. A Reason to Hope Lecture  
Hillman Cancer Center, Pittsburgh, PA  
01/23/03
32. "Surgical Management of Advanced GI Cancers"  
Murtha Cancer Center, Johnstown, PA  
04/08/03

33. "Hyperthermic Chemoperfusion for Regionally Confined Metastatic Cancer."  
Portsmouth US Naval Base, Portsmouth, VA  
01/27/04
  34. "Hyperthermic Chemoperfusion for Regionally Confined Metastatic Cancer"  
Maine Medical Center, Portland, Maine. The Isaac M. Weber Lecture  
05/13/04
  35. "Management of Hepatic Metastases"  
Maine Medical Center, Portland, Maine  
05/13/04
  36. "Hyperthermic Chemoperfusion for Regionally Confined Metastatic Cancer"  
St. Luke's Hospital, Allentown, PA  
05/20/04
  37. "Liver Surgery"  
Congress on Multidisciplinary Treatment of Liver Cancer, Catania, Italy  
October 13, 2005
- 

## **PROFESSIONAL ACTIVITIES**

### **TEACHING:**

Saturday Morning Case Conference – 3<sup>rd</sup> Year Medical Students – 2002-present  
Resident and Fellow precepting in OR – 16 hr/week – 2001 – present  
Resident and fellow precepting in clinic – 8hr/week  
Lab fellow mentoring (see following pages).



Current and Past Trainees of David Bartlett, MD.

<u>Name</u>	<u>Date/Place Of Degree</u>	<u>Training Period</u>	<u>Current Position</u>	<u>Project</u>
Sricharin Chaikondra, MD	1999, U. Pittsburgh	2004-present	Research Fellow Department of Surgery University of Pittsburgh	Enhancing vaccinia viral replication in the presensitized host utilizing immunosuppression.
Stephen Winikoff, M.D.	1997, Columbia U. New York	2003-present	Research Fellow Department of Surgery University of Pittsburgh	Vaccinia virus-mediated cancer therapy
Siamak Mohammadi, M.D.	1997 Cambridge U.	2002-present	Resident, Dept. of Surgery University of Pittsburgh	Construction of a gene regulated system in vaccinia virus
Xiaoyu Yin, Ph.D.	1992, 99 Guangzhou U. China	2003-present	Research Associate University of Pittsburgh	Vaccinia virus-mediated cancer therapy and identification of cancer antigens in cancers
Shuting Yang, Ph.D.	2003 U. of Pittsburgh	2003-present	Research Associate University of Pittsburgh	Enhance tumor selectivity through deletion of vaccinia another apoptosis-inhibiting genes (F1L) and combined deletion of SPI-1 & SPI-2
Charles K. Brown, M.D., Ph.D.	1992 University of Florida College of Medicine Gainesville, Florida	1995-1997	Assistant Professor Dept. of Surgery University of Pittsburgh	Biological Therapy for Cancer
Markus Puhlman, M.D.	1994, Germany	1995-1998	Unknown	Vaccinia expression of Suicide genes
Bernard Park, M.D.	U. of Pennsylvania	1996-1998	Attending – MSKCC	Melanoma specific transcriptional regulation
Maryann Kivlen, MD	1996 Albert Einstein College	1998-2000	Fellow – Surgical Oncology University of Pittsburgh	Targeting vaccinia through mutated envelope proteins
John Lee, M.D.	2003, Rush Medical College	1998-2000	Surgical Resident Cornell	Modulating the immunologic response to vaccinia oncolytic therapy
Kathy Hu, M.D.	2004 U. of Virginia	1999-2000	Ophthalmology Resident Wills Eye Institute Philadelphia, PA	Characterization of Yaba-like disease virus as an oncolytic virus

Bartlett, David L. 2006

**Current and Past Trainees of David Bartlett, MD., (cont)**

<u>Name</u>	<u>Date/Place Of Degree</u>	<u>Training Period</u>	<u>Current Position</u>	<u>Project</u>
Arpana Naiak, M.D.	1996 NYU School of Med.	1999-2001	Surgical Oncology Fellow MSKCC	Effects of WR vaccinia mutants in non-human pirates
Mathgan Kavanagh, M.D.	1997 UCLA School of Med.	1999-2001	Surgical Oncology Fellow John Wayne Cancer Center	Vaccinia expressing FAS L-immunologic consequence
Xhong Hui Wang, Ph.D.	1994, U. of Beijing	1997-2000	Unknown	Tumor specific replicating adenovirus

## RESEARCH

### CURRENT

Pittsburgh Foundation (PI)

7/1/2002-6/30/2006

20%

Isolated Hepatic Perfusion with Oxaliplatin for Colorectal Liver Metastases.

\$150,000

The major goal of this project is to provide for better regional treatments for liver tumors that may lead to cures or survival prolongation in patients who otherwise have no viable therapeutic options using Oxaliplatin.

R01 CA100415-01

NIH (PI)

3/1/2004-2/29/2008

20%

\$1,189,733

Development of a Tumor Selective Replicating Vaccinia

The goal is to explore any advances over our current vector in clinical trials in metastatic gastrointestinal cancers. The research will not only help develop vaccinia virus as a vector but should have implications for other replicating vectors used for cancer gene therapy.

Celegene (PI)

4/1/2002-3/31/2006

\$40,000

A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients with Recurrent Colorectal Cancer.

PO1CA 101944-01

NIH (Co-I)

4/1/04 - 6/30/10

5% (Project 3A)

Integrating NK and DC into Cancer Therapy

\$19,811,383

Program Leaders: Michael T. Lotze and Ronald Herberman

The goal is to integrating NK and DC into Cancer therapy directly into tumor or ex vivo administered as an immunogen will result in tumor destruction and elicit an effective adaptive immune response. The identification of critical biomarkers and surrogates using modern proteomic, genomic and cellomic strategies will be integrated into all projects.

**Research (continued)**

1P01 (CA 100327

NIH : Co-I

5/1/05 – 11/30/10

7.5% effort

\$4,500,00

Cytokine Gene Therapy for Cancer: Preclinical Models

Evaluation of combinational cytokine gene therapies (CGT) for the treatment of peripheral cutaneous or intracranial tumors in mice. Project 2 will evaluate the impact of combinational DC-based vaccines and IL-12 CGT for treating the spontaneous metastatic B16-BL6 melanoma model. Assessment of Th functional subsets and epitope spreading in therapeutic responses.

## **LIST of CURRENT RESEARCH INTERESTS:**

### **Development of tumor selective viral vectors and development of surgical procedures for the regional treatment of malignant neoplasms**

#### *Summary:*

The laboratory is developing viral vectors which can be administered systemically to a tumor-bearing host, and selectively target tumor cells for the expression of genes for enzyme/prodrug therapy and local immune responses. We have shown that a vaccinia virus which has a deletion in the thymidine kinase gene specifically replicates in tumor tissue in vivo and expresses high levels of a marker gene selectively in tumor cells. This selective expression can be translated into improved survival and cures when the virus expresses either the cytosine deaminase gene (converts nontoxic 5-FC to toxic 5-FU) or purine nucleoside phosphorylase gene (converts nontoxic 6-MPDR to toxic 6-MP) in a murine model of hepatic metastases from colorectal cancer. In addition, treatment with the prodrug can rescue the mice from toxic effects of the virus. We have now isolated a vaccinia mutant which has a deletion in both the thymidine kinase and vaccinia growth factor (VGF) genes.

It has previously been shown that a deletion in VGF markedly attenuates the virus in normal tissues, but replication in transformed cells is unaffected. This double mutant may allow for improved tumor selectivity and improved therapeutic results. We have completed a non-human primate study demonstrating the safety of this deleted vector in an isolated limb perfusion. In parallel with the study of new virus is the development of more potent and specific enzyme/prodrug systems. We are constructing a virus which expresses a fusion gene combining a secreted B-lactamase and the scFv against a melanoma antigen. B-lactamase can convert nontoxic cephalosporin conjugated chemotherapeutic agents into toxic agents. This protein may expand the toxic effect beyond the cells expressing the gene, while maintaining specificity for melanoma.

Because neutralizing antibodies to vaccinia in patients immunized against small pox may prevent viral infection and gene expression, we are exploring other pox vectors which may have similar selectivity without cross reactivity. We have shown that the yaba like disease (YLD) virus can be grown in high titres in CV-1 cells, similar to vaccinia, and that it infects human cell lines. We have shown that it does not cross react with vaccinia antibodies. We have sequenced the YLD thymidine kinase gene and created a recombinant virus expressing a marker gene (green fluorescent protein). We have found that this recombinant YLD infects, replicates, and efficiently expresses genes in certain human tumors. We are in the process of testing this virus as a gene delivery vector in vivo with human tumors in nude mice.

We are also exploring other potential therapeutic transgenes that induce non-specific local inflammation, which may lead to a bystander killing of un-infected tumor cells, including fas ligand, superantigen, and GmCSF.

As part of our clinical effort in regional therapy for metastatic cancer, we have developed hyperthermic peritoneal perfusion for peritoneal carcinomatosis. This has been developed in a phase I trial with cisplatin delivered intraoperatively in the context of surgical debulking and hyperthermia. Extensive cisplatin pharmacokinetics have been performed, describing this system. This has been extended to include post-operative dwell chemotherapy with paclitaxel and f-FU, and a phase I trial escalating these agents in the early post-operative period has been completed. We are now testing it in a trial for peritoneal mesothelioma, mucinous appendiceal cancer, and colon cancer with peritoneal metastases. The most promising results have been seen with peritoneal mesothelioma, where many patients have had complete resolution of ascites, prolonged disease free intervals, and responses to re-treatment.

We are also developing a simplified technique for isolated liver perfusion for patients with unresectable metastatic tumors in the liver. We originally described a 75 to 80 percent response rate for various histologies after a single 60-minute perfusion with melphalan and TNF. We have continued to use melphalan alone with similar response rates, and in some cases have included a post-operative infusional regimen of FUDR-leucovorin via an implantable pump in order to improve the durability of the response. In colorectal cancer, the median duration of response has been 14.5 months. This technique of isolated hepatic perfusion has taken a mean of 8 hours in the operating room and a hospital stay of 10 days. Our current goal is to simplify the procedure to allow for widespread applicability.

Finally, combining our expertise in regional delivery and gene therapy leads to the regional delivery of poxviruses for cancer gene therapy. We have completed primate studies, which demonstrate the ability for an isolated hyperthermic perfusion to deliver poxvirus to the tissues, improve the safety over intravenous injection, and avoid circulating antibody neutralization. We are developing clinical trials with this treatment strategy.

#### **OTHER RESEARCH RELATED ACTIVITIES:**

Ad hoc reviewer: Clinical Cancer Research, Cancer Research, Gene Therapy, Human Gene Therapy

Extra mural grant reviewer: Pittsburgh Foundation

Scientific Program Director, Society of Surgical Oncology 2005 Annual Meeting

#### **SERVICE:**

##### **University and Medical School**

2001 - present - Chief, Division of Surgical Oncology

2001 - present - UPCI Executive Cancer Committee Member

2001 – present - UPCI Clinical Council Member

2001 - present - Director, Surgical Oncology Fellowship Program  
2001 - present - Chair, Surgical Oncology Selection Committee  
2004 - present - Director, David C. Koch Regional Perfusion Cancer Therapy Center